ENA Respiratory Advances INNA-051 Into Part B Phase IIa
MELBOURNE, Australia — September 15, 2026 ENA Respiratory announced that the first participants have been dosed in Part B...
RSV
Advertisement
AdJane Unveils mRNA Mucosal Booster Vaccine Strategy
Delft, The Netherlands, September 10, 2026 AdJane Biosciences has announced the publication of a new white paper, “Boosting mRNA:...
ArkBio Advances Ziresovir in FDA-Approved Phase II RSV Trial
Shanghai, China, August 14, 2026 Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced that the U.S. Food and Drug Administration...
Co-Diagnostics Submits FDA 510(k) for PCR Respiratory Test
Salt Lake City, Utah, USA, August 7, 2026 Co-Diagnostics, Inc. has reached a major regulatory milestone by submitting a...
Merck FDA Accepts ENFLONSIA sBLA for Second RSV Season
RAHWAY, N.J., August 6, 2026 Merck announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental...
Advertisements
Co-Diagnostics Completes Validation for FDA 510(k) Submission
SALT LAKE CITY, Utah, July 1, 2026 Co-Diagnostics, Inc. has reached a significant regulatory milestone by completing the clinical...
Merck ENFLONSIA Approved in EU for Infant RSV Protection
RAHWAY, N.J., April 17, 2026 Merck & Co., Inc. announced that the European Commission (EC) has approved ENFLONSIA™ (clesrovimab),...
Gilead Showcases New Virology Data Spanning HIV, Hepatitis, and respiratory diseases
Foster City, California – October 20, 2025 — Gilead Sciences, Inc. (Nasdaq: GILD) announced that it will present new...
Sanofi Strengthens Vaccine Pipeline with Acquisition of Vicebio
Paris, France — August 21, 2025 – Sanofi has announced the acquisition of Vicebio, a biotechnology company specializing in...
Advertisement
